Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RespiVert Ltd.

Division of Johnson & Johnson
www.respivert.com

Latest From RespiVert Ltd.

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical

Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC

Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.

Deals M & A

F-Prime Plays The Long Game In Health Care Investing

With strong backing, F-Prime Capital Partners can make large, high-risk bets around the world — and keep doubling down. An interview with F-Prime Managing Partner Stephen Knight.

BioPharmaceutical

SkyePharma Refocuses On Drug Delivery After Drawn-Out Flutiform Development

With the combination asthma inhaler Flutiform being rolled out across Europe by licensee Mundipharma, the U.K.'s SkyePharma aims now to concentrate on drug delivery research, not clinical development.

BioPharmaceutical Europe
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register